NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biotechnology company focused on natural killer cell-based immunotherapies, with a pipeline targeting Alzheimer's disease and other neurodegenerative conditions. The company went public through a de-SPAC merger with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Acquisition Holdings IV LLC and led by James Graf, which completed its IPO in 2021. The business combination closed in September 2023, bringing NKGen to the public markets under the NKGN ticker on Nasdaq. The 10-Q filing dated August 16, 2021, accession number 0001104659-21-106424, represents an early disclosure in the company's public reporting history. For full filing history, pipeline data, and SPAC transaction details on NKGen Biotech and hundreds of other de-SPAC companies, sign up for a SpacDesk account at SpacDesk.com.